TroyGould Represents Lion Biotechnologies in $73.6 Million Public Offering
TroyGould PC represented Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products, in connection with its public offering of 9,200,000 shares of Lion’s common stock at $8 per share. The deal closed on March 3, 2015, with gross proceeds of $73.6 million.
Istvan Benko lead the transaction with the assistance of associate Dietrick Miller.
Latham & Watkins LLP in San Diego represented the underwriters.